BIOPHARMA SOLUTIONS™
Expedite Your Drug Development Program
Maximize the Value of Your Asset

The drug development journey can be complex and stressful. But, it doesn’t have to be. Join the more than 600 biopharmaceutical companies each year that partner with Covance to help manage their novel drugs throughout the development continuum. Access deep expertise working with a team that has managed more than 1,800 unique molecules, 300 IND/CTA enabling programs and 125 First-in-Human (FIH) trials in the past five years and experience efficiencies that span preclinical, clinical and commercial phases.

With solutions specifically designed to meet the needs of biopharma companies you can save time and money while maintaining study quality and data integrity. Benefits include:

- A dedicated team, with broad therapeutic expertise, that delivers continuity through study concept and execution, regulatory submissions and clinical trials.
- A drug development approach that minimizes risk and maximizes opportunities.
- Flexible processes and simplified financial options that help you meet the goals and milestones of your investors.

Get an unprecedented continuity of science, regulatory and process strategies throughout your program — for a CRO partnership experience unlike any other.

<table>
<thead>
<tr>
<th>DISCOVERY</th>
<th>DEVELOPMENT</th>
<th>COMMERCIALIZATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>RESEARCH</td>
<td>PRECLINICAL</td>
<td>PHASE I</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PHASE II</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PHASE III</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PHASE IV</td>
</tr>
</tbody>
</table>

**Individual Milestone Solutions**

<table>
<thead>
<tr>
<th>Lead Optimization</th>
<th>Safety &amp; Efficacy</th>
<th>FIH</th>
<th>POC</th>
<th>Phase III-IV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Market Access</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Regulatory</td>
</tr>
</tbody>
</table>

**Early Phase Development Solutions**

<table>
<thead>
<tr>
<th>Lead Optimization through POC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Optimization through IND/CTA Enabling</td>
</tr>
<tr>
<td>IND/CTA Enabling</td>
</tr>
<tr>
<td>IND/CTA through FIH</td>
</tr>
<tr>
<td>IND/CTA through POC</td>
</tr>
<tr>
<td>Covance MarketPlace</td>
</tr>
</tbody>
</table>

**Full Development Solutions**

| Lead Optimization through Phase IV |
Optimize Your Probability of Success

Pharmaceutical and biotech companies have named Covance as their preferred partner for every stage of development.¹ Let’s connect to put the experience of the world’s largest drug development database to work on your program. Access a global infrastructure and industry-leading nonclinical, regulatory and clinical expertise ensuring a tightly aligned, continuous solution to bridge your journey across key development milestones.

▶ COVANCE MARKETPLACE
No matter what phase you are in, you can forge the right connection with potential partners, while safeguarding your asset through a unique networking solution called Covance MarketPlace.

▶ LEAD OPTIMIZATION
Minimize delays during the nonclinical and clinical stages of your drug development program by identifying the right molecule and minimizing risk.

▶ EARLY PHASE DEVELOPMENT SOLUTIONS
Access a consistent and dedicated drug development team with a single point of contact to advance your program seamlessly from nonclinical through FIH and proof-of-concept (PoC®) phases.

▶ LATE-STAGE CLINICAL DEVELOPMENT
Collaborate with a dedicated management team to efficiently navigate complexities and simplify trial protocols, optimize trial site location selection, quickly recruiting the right patient populations, improve trial technology and access insights from global regulatory experts.

▶ CMC SOLUTIONS
From analytical testing to life-cycle management, build a strong strategy and overcome analytical challenges through chemistry, manufacturing and controls support for both biologics and small molecule programs.

▶ CENTRAL LABORATORY SERVICES
Tap into the power of the world’s leading network of central and specialty laboratories to access a wide range of comprehensive solutions. From standard testing to customized assays, you’ll receive globally consistent and actionable data to meet your study’s financial and timeline milestones.

▶ REGULATORY AFFAIRS
Enjoy smooth regulatory approvals with a strategy that addresses audit, submission, publishing and post-licensing support. More than 150 regulatory affairs professionals in more than 14 countries are at your service.

▶ MARKET ACCESS AND COMMERCIALIZATION
Gain a clear understanding of your asset’s clinical and economic value in terms that resonate with payers, providers, patients, investors and potential pharma partners. By combining perspectives in safety, efficacy, quality and commercial potential, you can quickly reach decision points and increase your ROI.

¹ Source: Robert W. Baird & Co. survey data.
EXPEDITE YOUR DRUG DEVELOPMENT JOURNEY

Drug Product Optimization & Final Image Selection

QP, Q4, Q1, Q2, Q3, Q4, Q1, Q2, Q3, Q4

No Go/Go

Quarters 1, 2, 3, and 4

Final Image Selection

Pre-IND Meeting

Drug Product Optimization & Final Image Selection

QUARTER 1

YEARS 1

*Requires Exploratory IND

Exploratory Clinical Trials

(Average study length approx. 8-9 months.)

First-in-Human Study research clinic – a "hybrid design."

Toxicology

Recruitment for Phase IIa

QUARTER 3

YEARS 1

Phase IIa — Proof of Principle (PoP)/Development

(Usually requires two. Average study length approx. 12-18 months.)

Dose Confirmatory Study

TOX (Chronic Tox Studies)

TOX (DART — Developmental & Reproductive Tox)

QUARTER 4

YEARS 1

Phase IIb — Dose Confirmatory

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 1

YEARS 2

Phase III — Registrational Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 2

YEARS 2

Phase IIIb studies. Sponsor-initiated health

QUARTER 3

YEARS 2

Peri-approval Studies

(Usually requires 2. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 4

YEARS 2

Phase IV — Post-marketing Studies

(Usually requires 2. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 1

YEARS 3

Regenerative Medicine, Tox, Clinical

QUARTER 2

YEARS 3

Phase III — Registrational Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 3

YEARS 3

Phase IIIb studies. Sponsor-initiated health

QUARTER 4

YEARS 3

Peri-approval Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 1

YEARS 4

Phase IV — Post-marketing Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 2

YEARS 4

Phase IV — Post-marketing Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 3

YEARS 4

Phase IV — Post-marketing Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 4

YEARS 4

Phase IV — Post-marketing Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 1

YEARS 5

Regenerative Medicine, Tox, Clinical

QUARTER 2

YEARS 5

Phase IV — Post-marketing Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 3

YEARS 5

Phase IV — Post-marketing Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 4

YEARS 5

Phase IV — Post-marketing Studies

(Usually requires two. Average study length approx. 12-18 months.)

Regenerative Medicine, Tox, Clinical

QUARTER 1

YEARS 6

Regenerative Medicine, Tox, Clinical
Let's begin the conversation that can jump-start your drug development program. Contact your Covance Business Development Director to learn more about solutions designed specifically for biopharmaceutical companies, or visit www.covance.com/thebioexperience